The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027, which includes Novo Nordisk's blockbuster weight-loss drug Wegovy. Here's

Trump added Denmark to his growing list of tariff targets — including Canada, Mexico and China — as he has increasingly spoken of the U.S. taking Greenland off Denmark’s hands. Danish multinational pharmaceutical giant Novo Nordisk is the sole owner ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

European equities rose on Tuesday on relief that US President Donald Trump had refrained from immediately targeting the region with trade tariffs.

Mads Krogsgaard Thomsen, CEO of Novo Nordisk Foundation, discusses European competitiveness.

European shares held steady with slight gains in financials and healthcare despite global uncertainties over U.S. President Donald Trump's proposed tariffs. The market's cautious optimism was challenged by pressure on automakers and basic resources.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's largest healthcare company, with a market cap that topped $8

Indian equity markets ended positively, with the Nifty closing above 23,100 despite intraday volatility. The index rebounded strongly, forming a hammer candlestick pattern, indicating strong buying at lower levels and potential bullish momentum.

The Nifty fell significantly, closing 320 points lower at 23,025, weighed down by continuous foreign institutional investor (FII) selling, uncertainty surrounding Trump’s tariff policies, and weaker-than-anticipated Q3 earnings from several companies.

By Nikhil Sharma and Pranav Kashyap (Reuters) -European shares rose on Tuesday, buoyed by gains in the healthcare and luxury sectors, but the uptick was tempered by lingering uncertainties over U.S. President Donald Trump's proposed tariff measures following his inauguration.